Last reviewed · How we verify
Epiduo Topical Product
Epiduo combines adapalene (a retinoid) and benzoyl peroxide to reduce acne by normalizing skin cell turnover and killing acne-causing bacteria.
Epiduo combines adapalene (a retinoid) and benzoyl peroxide to reduce acne by normalizing skin cell turnover and killing acne-causing bacteria. Used for Acne vulgaris.
At a glance
| Generic name | Epiduo Topical Product |
|---|---|
| Sponsor | Padagis LLC |
| Drug class | Retinoid + peroxide combination |
| Target | Retinoic acid receptor (adapalene); bacterial cell membrane disruption (benzoyl peroxide) |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | Phase 3 |
Mechanism of action
Adapalene is a third-generation retinoid that binds to retinoic acid receptors to normalize follicular keratinization and reduce comedone formation. Benzoyl peroxide provides antimicrobial activity against Cutibacterium acnes (formerly Propionibacterium acnes) and has mild keratolytic effects. Together, these agents address multiple pathogenic factors in acne development.
Approved indications
- Acne vulgaris
Common side effects
- Erythema
- Dryness
- Peeling
- Irritation
- Photosensitivity
Key clinical trials
- Experience With Topical Acne Treatment (EARLY_PHASE1)
- Study to Demonstrate the Efficacy and Safety of Adapalene/Benzoyl Peroxide Topical Gel in Subjects With Acne Vulgaris (PHASE3)
- Long-term Study of Efficacy/Safety of Adapalene/Benzoyl Peroxide Topical Gel in Acne Vulgaris Subjects (PHASE3)
- A Treatment for Severe Inflammatory Acne Subjects (PHASE4)
- A Treatment Regimen for Student Athletes With Mild to Moderate Acne Vulgaris (PHASE4)
- Effects of Oral Zinc Gluconate Among Acne Vulgaris Patients (PHASE4)
- Bioequivalence Study of Two Treatments in the Treatment of Acne Vulgaris on the Face (PHASE3)
- Anti-acne Efficacy of a Dermo-cosmetic Product Associated With the Fixed Combination Adapalene 0.1%/ Benzoyl Peroxide 2.5% Treatment Versus This Treatment Associated With a Standard Moisturizer in Male and Female Subjects Presenting With Mild to Moderate Acne (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Epiduo Topical Product CI brief — competitive landscape report
- Epiduo Topical Product updates RSS · CI watch RSS
- Padagis LLC portfolio CI